Full-Time

Staff Software Engineer

Updated on 9/4/2026

Verily

Verily

1,001-5,000 employees

Precision health tech leveraging data science

Compensation Overview

CA$175k - CA$197k/yr

+ Bonus + Equity

Toronto, ON, Canada + 1 more

More locations: Waterloo, ON, Canada

Hybrid

Bachelor's, Bachelor of Arts (BA), Bachelor of Science (BS)

Category
Software Engineering (1)
Required Skills
Microsoft Azure
Python
JavaScript
Apache Beam
Git
SQL
Java
ETL
Docker
C#
AWS
Go
Terraform
Objective-C
C/C++
Google Cloud Platform

Get referred to Verily

See people who can refer or advise you

Requirements
  • A BA/BS degree in Computer Science or Electrical Engineering, or equivalent practical experience in software development.
  • At least 10 years of experience as a software developer in an industry setting.
  • Ability to work independently and collaborate effectively.
  • Expertise building software and systems on Google Cloud Platform, Amazon Web Services, or Microsoft Azure; Google Cloud Platform is preferred.
  • Experience with one or more general-purpose programming languages, including Java, C/C++, C#, Objective-C, Go, Python, or JavaScript.
  • Qualified candidates must be legally authorized to work in Canada.
Responsibilities
  • Work closely with the development team to design, develop, and deliver new software features across the Verily technology stack.
  • Develop ideas for technical design problems, compare options, and propose solutions.
  • Develop using industry-standard tools including GitHub, Google Cloud, Go, Docker, and Terraform.
Desired Qualifications
  • Demonstrated experience with Go, Java, Python, and/or SQL.
  • Proficiency in Apache Beam and its associated technologies for data ingestion and processing.
  • Solid understanding of extract, transform, and load principles and best practices.
  • Experience designing and implementing scalable data processing pipelines with Bioquery or other analytics-oriented databases.
  • Education or exposure to healthcare or life sciences, with emphasis on HL7 FHIR.
  • Experience with Google Cloud Platform is preferred.

Verily Life Sciences uses data science and clinical expertise to improve health outcomes through precision health. It combines medical, lifestyle, and environmental data to tailor interventions, offering products like the Baseline Platform for clinical research and COVID-19 testing, care management solutions, and medical devices. It differentiates itself by integrating diverse data at scale, pursuing health equity through Onduo, and collaborating with public sector partners while maintaining strong data security and privacy. The goal is to uncover new health insights and bring precision health to everyone, improving health outcomes across populations.

Company Size

1,001-5,000

Company Stage

Late Stage VC

Total Funding

$3.8B

Headquarters

San Francisco, California

Founded

2015

Get referred to Verily

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • March 19, 2026 Verily raised $300 million to fund AI precision health expansion.
  • April 14, 2026 Workbench became generally available on AWS, broadening enterprise adoption.
  • February 2026 Segmed and March 2026 Samsung deals expand Verily’s research dataset moat.

What critics are saying

  • June 2025 layoffs cut 15% and ended devices programs, signaling weak product-market fit.
  • March 2026 Alphabet lost control, weakening Verily’s strategic safety net and cash support.
  • If Pre and Workbench fail to monetize fast, Verily becomes a stranded data-platform shell.

What makes Verily unique

  • Verily combines clinical data, wearables, and research workflows in one governed platform.
  • March 2026 Samsung and Salesforce partnerships widen Verily’s data distribution.
  • Verily Workbench on AWS lowers friction for enterprise biomedical AI teams.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

0%
University of Bath
Aug 26th, 2026
Global initiative will harness wastewater as an early warning system for public health protection.

Global initiative will harness wastewater as an early warning system for public health protection. Labs across the world will collect wastewater samples on Global Wastewater Day in 2027 to generate a unique snapshot of international public health. * Press release * Published on Wednesday 26 August 2026 * Last updated on Wednesday 26 August 2026 * View more announcements in Communications Researchers from CWBE at the University of Bath partnered with Bangor University have launched Global Wastewater Day (GWD), a pioneering international initiative to harness wastewater as an early warning system for future pandemics. The initiative will bring together scientists, governments, water utilities and public health organisations from around the world to establish one of the first coordinated global wastewater intelligence networks to transform wastewater from an overlooked by-product into one of the world's most powerful tools for understanding public health, environmental change and emerging global risks. The initiative aims to create a simultaneous global snapshot of health and environmental conditions through wastewater analysis, generating new insights to strengthen disease surveillance, track antimicrobial resistance, protect the environment and improve pandemic preparedness. Professor Davey Jones, from Bangor University (Wales), who is the leading the partnership, launched the initiative at the World Water Week conference in Stockholm, which brought together experts, policymakers, businesses and international organisations from across the globe. The project will coordinate a single, global day of wastewater sampling on 31 March 2027, with participating partners analysing wastewater at host labs across the world. Professor Barbara Kasprzyk-Hordern, Global Wastewater Day co-chair and Director of the University of Bath's Centre of Excellence in Water-Based Early-Warning Systems for Health Protection (CWBE), will provide the steer and deliver the chemical analysis programme of global wastewater samples with centre's new cutting-edge mass spectrometry facility. Professor Julie Barnett, Social Sciences Lead at CWBE, has also joined GWD steering committee to coordinate the ethical oversight of the initiative. The aim is to generate the first synchronised snapshot of global public health using wastewater-based epidemiology (WBE). Using established and cutting-edge methods, the programme will focus on detecting antimicrobial resistance (AMR), pathogens, pharmaceuticals, chemical indicators and other markers of human health. The initiative is being delivered in partnership between the University of Bath, Bangor University, Verily Health, the Global Consortium for Wastewater and Environmental Surveillance for Public Health (GLOWACON), the European Commission Joint Research Centre, and a growing international consortium of scientific and public health organisations. By capturing comparable information from communities around the world, Global Wastewater Day seeks to establish a new global benchmark for monitoring health and environmental change. With over 31 countries signed up to date, the initiative's long-term ambition is to create a "Planetary Health Observatory" where wastewater becomes a routine source of intelligence for understanding the interconnected health of people, animals and the environment. Professor Barbara Kasprzyk-Hordern, Director of CWBE at the University of Bath, said: "I am delighted to see this unique initiative moving forward. "Global Wastewater Day provides an important opportunity to highlight the vital role of Wastewater-Based Epidemiology in protecting public health, safeguarding the environment, and driving sustainable innovation. "As a powerful tool for monitoring population health and environmental trends, wastewater analysis will deliver actionable insights that support evidence-based decision-making and help build more resilient and sustainable communities worldwide. "With cutting-edge analytical capabilities we will generate unprecedented insights into population health, including the burden of non-communicable diseases such as diabetes and cardiovascular disease, dietary and nutritional patterns, and exposure to hazardous chemicals, including PFAS." Davey Jones, Professor of Environmental Science and Public Health at Bangor University, said: "Everything Bath do in society leaves a footprint in its wastewater. "With Global Wastewater Day Bath want to harness the information it provides to supercharge public health research across the world, helping Bath detect emerging threats earlier and build a stronger early-warning system for future pandemics. "The initiative will enable a global comparison of public health data using standardised methods, while building a long-term resource through annual repeat sampling and an open-access dataset. "A core principle of the project is accessibility and inclusivity, with a strong emphasis on supporting participation from low- and middle-income countries. "Bath want to encourage as many scientists, organisations and communities as possible to get involved, contribute data and expertise, and share the initiative with colleagues and networks who may be interested. "By working across borders, we have an unprecedented opportunity to transform wastewater from an overlooked resource into a source of global intelligence, helping to protect populations, strengthen resilience and support better decision-making for future generations." Organisations and researchers are invited to register their interest in taking part in Global Wastewater Day. Media enquiries.

MPO Magazine
May 28th, 2026
Verily raises $300M to advance AI precision health platform

Verily has raised $300 million in a funding round led by Series X Capital, with participation from Alphabet, UCHealth, the University of Colorado Anschutz and others. Alphabet remains a significant minority investor but no longer holds a controlling stake in the precision health AI company. The investment marks Verily's transition from an LLC to a corporation, now officially named Verily Health Inc. The funds will accelerate its AI-native precision health platform strategy, helping customers harmonise healthcare data and deploy actionable intelligence into research and care workflows. Verily recently announced partnerships with Samsung's Galaxy Watch and Salesforce's Agentforce Health. The company, which graduated from Google X 10 years ago as one of Alphabet's earliest ventures, aims to make healthcare more personalised, predictive and precise through AI-powered solutions.

FCC Singapore
May 26th, 2026
Verily, a Google subsidiary, expands its mosquito factory in Singapore to strengthen dengue control.

Verily, a Google subsidiary, expands its mosquito factory in Singapore to strengthen dengue control. 26 May 2026 [PHOTO: The Straits Times] Market Info | Health & Lifestyle | Public Health Date: 1 June 2026 Region: ASEAN-O Country: Singapore Sector: Health & Lifestyle Sub-sector: Public Health Section: Market Trends Theme: Combating Infectious Diseases Verily, a subsidiary of tech giant Google, has announced a significant expansion of its sterile mosquito production facility in Singapore, marking a major milestone in the fight against dengue. This initiative leverages cutting-edge technology where sterile male mosquitoes are bred and released into the wild to mate with wild females, thereby reducing the population of mosquitoes capable of transmitting diseases like dengue. This method, known as the Sterile Insect Technique (SIT), is an eco-friendly alternative to traditional pesticides and aligns with a sustainable approach to vector control. The expansion of this facility in Singapore reflects the country's commitment to strengthening its public health capabilities in the face of challenges posed by vector-borne diseases. Dengue, in particular, remains a major concern in the region, with thousands of cases reported annually. By adopting this innovative technology, Singapore demonstrates its determination to combine science and public health to protect its population. This approach also aligns with the broader objectives of the Healthier SG strategy, which aims to enhance the resilience of the healthcare system against emerging threats. Furthermore, this initiative positions Singapore as a regional leader in biotechnology applied to public health. By collaborating with international players like Verily, the country strengthens its ability to innovate and attract investments in sustainable health solutions. Verily's sterile mosquito factory in Singapore could also serve as a model for other countries in the region facing similar challenges with mosquito-borne diseases. This expansion is a tangible example of how Singapore is leveraging technology and innovation to address complex public health challenges while contributing to global solutions for infectious disease control.

MPO Magazine
Apr 30th, 2026
Segmed, Verily band together to expand access to real-world imaging data.

Segmed, Verily band together to expand access to real-world imaging data. Pairing aims to to support patient-centered, data-driven healthcare innovation. April 30, 2026 Managing Editor Segmed Inc. is partnering with Verily to increase access to de-identified imaging datasets. Through the collaboration, Segmed is making its de-identified, diagnostic-grade imaging and associated clinical data more available by enabling researchers to explore curated datasets within Verily's precision health platform, Pre Exchange and Workbench environment, secure platforms designed to accelerate precision health research and discovery. The partnership reflects Segmed's commitment to supporting rigorous, privacy-first research while lowering barriers to entry for investigators across academia, life sciences, and healthcare artificial intelligence (AI), Segmed executives claim. "Advanced imaging data plays a critical role in precision medicine, particularly when combined with clinical and other biomedical data modalities," Segmed CEO David Gascoigne said. "By partnering with Verily, we're expanding responsible access to high-quality, de-identified imaging datasets, helping researchers generate insights faster to accelerate the development of diagnostics and therapies." Segmed's initial dataset available through Pre Exchange focuses on breast cancer and includes a longitudinal cohort of patients who underwent at least one digital breast tomosynthesis (DBT) exam and biopsy-proven malignant lesions. This dataset is drawn from Segmed's broader global imaging platform, which includes approximately 150 million de-identified imaging exams spanning modalities such as CT, MRI, X-ray, ultrasound, mammography, PET, SPECT, echocardiography, and DEXA. "This partnership with Segmed is an important step forward in advancing AI-powered precision health," Verily Chief Revenue Officer Bharat Rajagopal stated. "By integrating Segmed's curated real-world imaging and associated clinical data into Pre, we are empowering researchers with the comprehensive, multimodal data resources they need to unlock new insights and accelerate discovery." This partnership reflects Segmed's ongoing efforts to support patient-centered, data-driven healthcare innovation by enabling secure, scalable access to real-world imaging data and associated clinical data within trusted research environments. Segmed Inc. streamlines access to diverse, high-quality real-world data, including medical imaging and clinical records, for biopharmaceutical R&D, AI development, and medical device innovation. With a global network of healthcare partners across five continents, Segmed provides researchers with approximately 150 million de-identified, standardized imaging datasets through its proprietary platform, empowering safer, faster, and more equitable healthcare advancements. Verily is a data platform and technology company purpose-built to power AI for precision health. Verily offers AI-enabled solutions that transform multimodal health data into insights and actions that accelerate research and improve care for individuals and communities. Verily is positioned at the intersection of technology, data science, and healthcare to create tools that accelerate evidence generation, enable more personalized care, and help manage disease at a population level.

Associated Press
Apr 14th, 2026
Verily Workbench launches on AWS to accelerate biomedical AI research

Verily Health has announced that Verily Workbench, its scalable trusted research environment for biomedical data analysis and AI development, is now generally available on Amazon Web Services. The platform enables researchers to analyse healthcare data with built-in compliance and integrated AI tools. Workbench offers zero cloud cost markup, allowing organisations to use existing AWS accounts and negotiated rates. The platform includes native integration with NVIDIA AI tools and supports multicloud operations across AWS and Google Cloud Platform. Researchers can access free standard tier accounts through Verily's Exchange solution. The platform currently serves life sciences, health system and government customers, including the NIH's All of Us Research Programme, which supports over 20,000 researchers worldwide. Verily holds SOC 2 Type 2 and ISO/IEC 27001 certifications.